In the Claims

1. (Withdrawn) A block copolymer comprising a fluorinated block and at least one non-fluorinated block, wherein the fluorinated block has the following structure:



; and

wherein the non-fluorinated block has the following structure:



,

wherein R_1 is selected from the group consisting of –CH_3, -CF_3, -CH_2CH_3, -$CH_2CH_2CH_3$, -$CH_2CH_2CH_2CH_3$, -phenyl, naphthyl, -$COOR_3$, and -$CONR_3R_4$;

wherein R_2 is selected from the group consisting of –H, –CH_3, -CF_3, -CH_2CH_3, -$CH_2CH_2CH_3$, -$CH_2CH_2CH_2CH_3$, -phenyl, and naphthalenyl; and

wherein R_3 and R_4 are selected from the group consisting of -CH_3, -CH_2CH_3, -$CH_2CH_2CH_3$, -$CH_2CH_2CH_2CH_3$, -CH_2CH_2OH, and –PEG.

2. (Withdrawn) The block copolymer of claim 1 having a formula of the following structure:



wherein R_1' is selected from the group consisting of -CH_3, -CH_2CH_3, -

$CH_2CH_2CH_3$, $-CH_2CH_2CH_2CH_3$, $-CH_2CH_2OH$, and -PEG, and

wherein R_2 is selected from the group consisting of –H or $–CH_3$, $-CF_3$, $-CH_2CH_3$, $-CH_2CH_2CH_3$, $-CH_2CH_2CH_2CH_3$, -phenyl and naphthyl.

3. (Withdrawn) The block copolymer of claim 2 wherein R_1' is $-CH_3$, $-CH_2CH_3$, $-CH_2CH_2CH_3$, $-CH_2CH_2CH_2CH_3$, $-CH_2CH_2OH$, or -PEG, and

wherein R_2 is –H or $–CH_3$.

4. (Withdrawn) A block copolymer comprising a fluorinated block and at least one non-fluorinated block, wherein the fluorinated block has the following structure:



; and

wherein the non-fluorinated block is a polymer selected from the group consisting of polyesters, polyethers, polyanhydrides, polyglycols, poly(alkylene oxides), polyhydroxyalkanoates, polyphosphazenes, polyurethanes, and a combination thereof.

5. (Withdrawn) A polymeric coating composition comprising a block copolymer which comprises a fluorinated block and at least one non-fluorinated block, wherein the fluorinated block has the following structure:



; and

wherein the non-fluorinated block has the following structure:



wherein R_1 is selected from the group consisting of $-CH_3$, $-CF_3$, $-CH_2CH_3$, $-CH_2CH_2CH_3$, $-CH_2CH_2CH_2CH_3$, -phenyl, naphthyl, $-COOR_3$, and $-CONR_3R_4$;

wherein R_2 is selected from the group consisting of –H, $-CH_3$, $-CF_3$, $-CH_2CH_3$, $-CH_2CH_2CH_3$, $-CH_2CH_2CH_2CH_3$, -phenyl, and naphthalenyl; and

wherein R_3 and R_4 are selected from the group consisting of $-CH_3$, $-CH_2CH_3$, $-CH_2CH_2CH_3$, $-CH_2CH_2CH_2CH_3$, $-CH_2CH_2OH$, and –PEG.

6. (Withdrawn) The coating composition of claim 5 wherein the block copolymer has a formula of the following structure:



wherein R_1' is selected from the group consisting of $-CH_3$, $-CH_2CH_3$, $-CH_2CH_2CH_3$, $-CH_2CH_2CH_2CH_3$, $-CH_2CH_2OH$, and -PEG, and

wherein R_2 is selected from the group consisting of –H or $-CH_3$, $-CF_3$, $-CH_2CH_3$, $-CH_2CH_2CH_3$, $-CH_2CH_2CH_2CH_3$, -phenyl and naphthyl.

7. (Withdrawn) The coating composition of claim 6 wherein R_1' is selected from the group consisting of $-CH_3$, $-CH_2CH_3$, $-CH_2CH_2CH_3$, $-CH_2CH_2CH_2CH_3$, $-CH_2CH_2OH$, or -PEG, and

wherein R_2 is –H or $-CH_3$.

8. (Withdrawn) A polymeric coating composition comprising a block copolymer which comprises a fluorinated block and at least one non-fluorinated block, wherein the fluorinated block has the following structure:



; and

wherein the non-fluorinated block is a polymer selected from the group consisting of polyesters, polyethers, polyanhydrides, polyglycols, poly(alkylene oxides), polyhydroxyalkanoates, polyphosphazenes, polyurethanes, and a combination thereof.

9. (Withdrawn) The coating composition of claim 5 further comprising a bioactive agent.

10. (Withdrawn) The coating composition of claim 6 further comprising a bioactive agent.

11. (Withdrawn) The coating composition of claim 7 further comprising a bioactive agent.

12. (Withdrawn) The coating composition of claim 8 further comprising a bioactive agent.

13. (Withdrawn) The coating composition of claim 9 wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, Everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

14. (Withdrawn) The coating composition of claim 10 wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin,

Everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

15. (Withdrawn) The coating composition of claim 11 wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, Everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

16. (Previously presented) An implantable device comprising a coating which comprises a block copolymer, the block copolymer comprising a fluorinated block and at least one non-fluorinated block, wherein the fluorinated block is a poly(fluoroalkene).

17. (Original) The implantable device of claim 16, wherein the fluorinated block has the following structure:



; and

wherein the non-fluorinated block has the following structure:



,

wherein R_1 is selected from the group consisting of –CH_3, -CF_3, -CH_2CH_3, -$CH_2CH_2CH_3$, -$CH_2CH_2CH_2CH_3$, -phenyl, naphthyl, -$COOR_3$, and -$CONR_3R_4$;

wherein R_2 is selected from the group consisting of –H, –CH_3, -CF_3, -CH_2CH_3, -$CH_2CH_2CH_3$, -$CH_2CH_2CH_2CH_3$, -phenyl, and naphthalenyl; and

wherein R_3 and R_4 are selected from the group consisting of -CH_3, -CH_2CH_3, -

$CH_2CH_2CH_3$, $-CH_2CH_2CH_2CH_3$, $-CH_2CH_2OH$, and –PEG.

18. (Original) The implantable device of claim 17, wherein the block copolymer has a formula of the following structure:



wherein R_1' is selected from the group consisting of $-CH_3$, $-CH_2CH_3$, $-CH_2CH_2CH_3$, $-CH_2CH_2CH_2CH_3$, $-CH_2CH_2OH$, and -PEG, and

wherein R_2 is selected from the group consisting of –H or $-CH_3$, $-CF_3$, $-CH_2CH_3$, $-CH_2CH_2CH_3$, $-CH_2CH_2CH_2CH_3$, -phenyl and naphthyl.

19. (Currently amended) The implantable device of claim 18 wherein R_1' is selected from the group consisting of $-CH_3$, $-CH_2CH_3$, $-CH_2CH_2CH_3$, $-CH_2CH_2CH_2CH_3$, $-CH_2CH_2OH$, ~~or~~ and -PEG, and

wherein R_2 is –H or $-CH_3$.

20. (Original) The implantable device of claim 16, wherein the fluorinated block has the following structure:



; and

wherein the non-fluorinated block is a polymer selected from the group consisting of polyesters, polyethers, polyanhydrides, polyglycols, poly(alkylene oxides), polyhydroxyalkanoates, polyphosphazenes, polyurethanes, and a combination thereof.

21. (Original) The implantable device of claim 16, which is a drug-eluting stent, wherein the coating further comprises a bioactive agent.

22. (Original) The implantable device of claim 17, which is a drug-eluting stent, wherein the coating further comprises a bioactive agent.

23. (Original) The implantable device of claim 18, which is a drug-eluting stent, wherein the coating further comprises a bioactive agent.

24. (Original) The implantable device of claim 19, which is a drug-eluting stent, wherein the coating further comprises a bioactive agent.

25. (Original) The implantable device of claim 20, which is a drug-eluting stent, wherein the coating further comprises a bioactive agent.

26. (Previously presented) The implantable device of claim 21, wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

27. (Previously presented) The implantable device of claim 22, wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

28. (Previously presented) The implantable device of claim 23, wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

29. (Previously presented) The implantable device of claim 24, wherein the

bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

30. (Previously presented) The implantable device of claim 25, wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

31. (Withdrawn) A method of treating restenosis or vulnerable plaque, comprising implanting in a human being in need thereof the implantable device of claim 16.

32. (Withdrawn) A method of treating restenosis or vulnerable plaque, comprising implanting in a human being in need thereof the implantable device of claim 17.

33. (Withdrawn) A method of treating restenosis or vulnerable plaque, comprising implanting in a human being in need thereof the implantable device of claim 26.

34. (Withdrawn) A method of treating restenosis or vulnerable plaque, comprising implanting in a human being in need thereof the implantable device of claim 27.

35. (Withdrawn) A method of treating restenosis or vulnerable plaque, comprising implanting in a human being in need thereof the implantable device of claim 28.

36. (Withdrawn) A method of synthesizing a block copolymer comprising a

fluorinated block and at least a block of the following structure:



, comprising copolymerizing a monomer having the structure of



in the presence of a di-halo macromer,

wherein R_1 is selected from the group consisting of –CH_3, -CF_3, -CH_2CH_3, -$CH_2CH_2CH_3$, -$CH_2CH_2CH_2CH_3$, -phenyl, naphthyl, -$COOR_3$, and -$CONR_3R_4$;

wherein R_2 is selected from the group consisting of –H, –CH_3, -CF_3, -CH_2CH_3, -$CH_2CH_2CH_3$, -$CH_2CH_2CH_2CH_3$, -phenyl, and naphthalenyl; and

wherein R_3 and R_4 are selected from the group consisting of -CH_3, -CH_2CH_3, -$CH_2CH_2CH_3$, -$CH_2CH_2CH_2CH_3$, -CH_2CH_2OH, and –PEG, and

wherein the di-halo macromer is selected from the group consisting of di-chloro macromer, di-bromo macromer, di-iodo macromer and a combination thereof.

37. (Withdrawn) The method of claim 36 wherein the di-halo macromer is formed by polymerizing a fluorinated olefin in the presence of a dihalide.

38. (Withdrawn) The method of claim 37 wherein the fluorinated olefin is selected from the group consisting of vinylidene fluoride, hexafluoropropylene, tetrafluoroethylene, and a combination thereof.

39. (Withdrawn) The method of claim 38 wherein the di-halo macromer is prepared by polymerizing a mixture of vinylidene fluoride and 1,1,2,3,3,3-hexafluoropropylene in the presence of 1,2-diiodo-1,1,2,2-difluoroethylene.

40. (Withdrawn) The method of claim 39 the di-halo macromer has a structure of